Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

被引：0
作者：
A. I. Daud
C. Xu
W.-J. Hwu
P. Urbas
S. Andrews
N. E. Papadopoulos
L. C. Floren
A. Yver
R. C. DeConti
V. K. Sondak
机构：
[1] University of California,Division of Hematology/Oncology
[2] San Francisco,Department of Cutaneous Oncology
[3] Merck Research Laboratories,Department of Oncologic Sciences
[4] M.D. Anderson Cancer Center,Department of Bioengineering and Therapeutic Sciences
[5] H. Lee Moffitt Cancer Center and Research Institute,Division of Hematology/Oncology, Melanoma Program
[6] University of South Florida College of Medicine,undefined
[7] University of California,undefined
[8] San Francisco,undefined
[9] AstraZeneca Pharmaceuticals LP,undefined
[10] University of California,undefined
[11] San Francisco,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Peginterferon α-2b; Melanoma; Adjuvant therapy; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 666
页数：9
相关论文
共 70 条
  • [1] Foster GR(2004)Review article: pegylated interferons: chemical and clinical differences Aliment Pharmacol Ther 20 825-830
  • [2] Bukowski R(2002)Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study J Clin Oncol 20 3841-3849
  • [3] Ernstoff MS(1996)Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 7-17
  • [4] Gore ME(2000)High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2444-2458
  • [5] Kirkwood JM(2001)High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2370-2380
  • [6] Strawderman MH(2006)Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma Cancer 106 1431-1442
  • [7] Ernstoff MS(2007)Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials J Clin Oncol (Meeting Abstracts) 25 8526-3718
  • [8] Smith TJ(2002)Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy J Clin Oncol 20 3703-2848
  • [9] Borden EC(2004)Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2839-1155
  • [10] Blum RH(2005)Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial Dig Dis Sci 50 1148-403
1234567